PMID- 25071563
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140729
LR  - 20211021
IS  - 1663-4365 (Print)
IS  - 1663-4365 (Electronic)
IS  - 1663-4365 (Linking)
VI  - 6
DP  - 2014
TI  - The potential applications of Apolipoprotein E in personalized medicine.
PG  - 154
LID - 10.3389/fnagi.2014.00154 [doi]
LID - 154
AB  - Personalized medicine uses various individual characteristics to guide medical 
      decisions. Apolipoprotein (ApoE), the most studied polymorphism in humans, has 
      been associated with several diseases. The purpose of this review is to elucidate 
      the potential role of ApoE polymorphisms in personalized medicine, with a 
      specific focus on neurodegenerative diseases, by giving an overview of its 
      influence on disease risk assessment, diagnosis, prognosis, and therapy. This 
      review is not a systematic inventory of the literature, but rather a summary and 
      discussion of novel, influential and promising works in the field of ApoE 
      research that could be valuable for personalized medicine. Empirical evidence 
      suggests that ApoE genotype informs pre-symptomatic risk for a wide variety of 
      diseases, is valuable for the diagnosis of type III dysbetalipoproteinemia, 
      increases risk of dementia in neurodegenerative diseases, and is associated with 
      a poor prognosis following acute brain damage. ApoE status appears to influence 
      the efficacy of certain drugs, outcome of clinical trials, and might also give 
      insight into disease prevention. Assessing ApoE genotype might therefore help to 
      guide medical decisions in clinical practice.
FAU - Villeneuve, Sylvia
AU  - Villeneuve S
AD  - Department of Medicine, ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, 
      Universite de Montreal Chicoutimi, QC, Canada ; Helen Wills Neuroscience 
      Institute, University of California Berkeley, CA, USA.
FAU - Brisson, Diane
AU  - Brisson D
AD  - Department of Medicine, ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, 
      Universite de Montreal Chicoutimi, QC, Canada.
FAU - Marchant, Natalie L
AU  - Marchant NL
AD  - Department of Old Age Psychiatry, Institute of Psychiatry, King's College London 
      London, UK.
FAU - Gaudet, Daniel
AU  - Gaudet D
AD  - Department of Medicine, ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, 
      Universite de Montreal Chicoutimi, QC, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140708
PL  - Switzerland
TA  - Front Aging Neurosci
JT  - Frontiers in aging neuroscience
JID - 101525824
PMC - PMC4085650
OTO - NOTNLM
OT  - Alzheimer disease
OT  - ApoE
OT  - cardiovascular diseases
OT  - diagnosis
OT  - neurodegenerative diseases
OT  - prognosis
OT  - risk
OT  - treatment
EDAT- 2014/07/30 06:00
MHDA- 2014/07/30 06:01
PMCR- 2014/01/01
CRDT- 2014/07/30 06:00
PHST- 2014/03/18 00:00 [received]
PHST- 2014/06/18 00:00 [accepted]
PHST- 2014/07/30 06:00 [entrez]
PHST- 2014/07/30 06:00 [pubmed]
PHST- 2014/07/30 06:01 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - 10.3389/fnagi.2014.00154 [doi]
PST - epublish
SO  - Front Aging Neurosci. 2014 Jul 8;6:154. doi: 10.3389/fnagi.2014.00154. 
      eCollection 2014.